Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale

Peptone is proud to announce a strategic partnership with Evotec aimed at accelerating and scaling the creation of small molecule therapeutics targeting intrinsically disordered proteins (IDPs) across diverse therapeutic areas. This collaboration uniquely combines Peptone’s pioneering physics-based HDX-MS platform for identifying novel IDP pockets with Evotec’s extensive drug discovery toolbox, including deep assay expertise, medicinal chemistry, and state-of-the-art screening capabilities. By integrating our distinct strengths, we aim to unlock therapies against previously intractable proteins and enable the rapid and efficient development of viable drug candidates.

About Evotec

Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-powered platforms and advanced technologies, we accelerate the creation of life-changing medicines — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, and cell therapies, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.

With flexible partnering models tailored to our customers’ needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.

Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.

With a strong portfolio of over 100 co-owned and proprietary R&D projects, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.

Evotec’s global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.

About Peptone

Peptone is a biotechnology company developing novel first-in-class small molecule therapeutics targeting intrinsically disordered proteins (IDPs) to treat diseases through a pioneering experimental approach that starts with studying the structural dynamics of IDPs. Peptone’s technology accurately translates bespoke experimental data into dynamic models of disordered proteins regardless of protein size or complexity with the necessary speed and insights to design therapeutics capable of affecting IDP function. The company’s initial focus is on oncology targets areas of highly unmet need with strong disease hypotheses and biological validation. For more information about Peptone, visit https://peptone.io.